Pentadecapeptide BPC (Oral)

Overview

Oral BPC-157 refers to stabilized oral preparations of the pentadecapeptide Body Protection Compound-157 (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val), most commonly the arginate salt (sometimes acetate or enteric-coated capsules), intended to survive gastric transit and improve absorption versus the unformulated peptide. This entry covers the salt/stabilized formulations specifically; generic BPC-157 capsules without a salt-form claim are classified under the base BPC-157 entry.

Mechanism of Action

The peptide portion shares the same proposed mechanism as injectable BPC-157 — NO-system modulation, VEGFR2 activation, FAK–paxillin signaling, and upregulation of growth factors involved in tissue repair — plus direct gastrointestinal mucosal contact for local effects on the GI lining. The arginine counter-ion is claimed to improve aqueous stability and resistance to acid-mediated degradation relative to the acetate form; comparative bioavailability claims circulating in marketing material come from vendor/patent sources rather than peer-reviewed human pharmacokinetic studies.

Research Summary

Sikiric and colleagues have published preclinical rat studies using peroral BPC-157 (typically 10 μg/kg or 10 ng/kg in drinking water) in models of gastric ulcer, colitis and ischemia–reperfusion, NSAID-induced GI damage, short bowel syndrome, and fistula healing, plus systemic models (tendon, liver, CNS). The peptide is reported stable in human gastric juice for more than 24 hours. No human clinical trials of the arginate, acetate, or enteric-coated oral formulations have been published, and there are no peer-reviewed head-to-head human PK comparisons between salt forms; bioavailability claims in marketing material trace to vendor/patent sources rather than peer-reviewed human data. Research-use only; not FDA-approved.

Reported Side Effects

• Mild nausea
• Gastrointestinal discomfort
• Headache
• Dizziness

Research References

• Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract (review of peroral dosing and gastric juice stability) (2011)
• Gastric pentadecapeptide BPC 157 and short bowel syndrome in rats (peroral administration in drinking water) (2009)
• Stable Gastric Pentadecapeptide BPC 157 and Wound Healing (gastric juice stability >24 h) (2021)

Frequently asked questions

Has Pentadecapeptide BPC (Oral) been independently lab-tested?

Disclosed Labs has collected 2 Certificates of Analysis (COA) for Pentadecapeptide BPC (Oral) from 2 independent testing labs. 2 vendors have submitted material for testing. Products average 99.5% tested purity across the corpus. Full testing data is available at https://www.disclosedlabs.com/peptides/oral-bpc-157/testing.

Which labs have tested Pentadecapeptide BPC (Oral)?

Independent labs that have tested Pentadecapeptide BPC (Oral) include: Ethos Analytics (Grade B). Full lab credibility grades and profiles are at https://www.disclosedlabs.com/labs.

How does Pentadecapeptide BPC (Oral) work?

The peptide portion shares the same proposed mechanism as injectable BPC-157 — NO-system modulation, VEGFR2 activation, FAK–paxillin signaling, and upregulation of growth factors involved in tissue repair — plus direct gastrointestinal mucosal contact for local effects on the GI lining. The arginine counter-ion is claimed to improve aqueous stability and resistance to acid-mediated degradation relative to the acetate form; comparative bioavailability claims circulating in marketing material come from vendor/patent sources rather than peer-reviewed human pharmacokinetic studies.

What does the research say about Pentadecapeptide BPC (Oral)?

Sikiric and colleagues have published preclinical rat studies using peroral BPC-157 (typically 10 μg/kg or 10 ng/kg in drinking water) in models of gastric ulcer, colitis and ischemia–reperfusion, NSAID-induced GI damage, short bowel syndrome, and fistula healing, plus systemic models (tendon, liver, CNS). The peptide is reported stable in human gastric juice for more than 24 hours. No human clinical trials of the arginate, acetate, or enteric-coated oral formulations have been published, and there are no peer-reviewed head-to-head human PK comparisons between salt forms; bioavailability claims in marketing material trace to vendor/patent sources rather than peer-reviewed human data. Research-use only; not FDA-approved.